Normunity Secures $75 Million to Advance Anti-Cancer Therapies
Normunity, a biotechnology company focused on developing novel anti-cancer therapies, has secured significant funding to advance its pipeline of innovative treatments. The company recently announced the closure of its Series B financing, raising $75 million to further its lead program and expand its portfolio of anti-cancer medicines.
This latest round of funding was co-led by Samsara BioCapital and Enavate Sciences, with participation from new investors Regeneron Ventures, Pfizer Ventures, and YK Bioventures, alongside existing investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut Innovations. The investment will enable Normunity to advance its lead program, NRM-823, a first-in-class T cell engager that targets a novel, highly specific tumor target expressed on multiple types of solid tumors.
NRM-823 is designed to bind to this tumor-specific target, leveraging the body’s immune system to combat cancer. The program is expected to enter the clinic in the second half of 2025, marking a significant milestone in Normunity’s mission to develop life-changing medicines for cancer patients. In addition to advancing NRM-823, the funding will also be used to broaden Normunity’s pipeline of anti-cancer therapies, focusing on novel targets that address untapped biology at the interface of the immune system and the tumor.
Normunity’s approach to cancer treatment is based on an ongoing, interactive academic-biotech alliance with the lab of Dr. Lieping Chen at Yale School of Medicine. This collaboration leverages proprietary discovery platforms to elucidate the complex interactions between human cancer and the immune system, identifying novel mechanisms of immune disruption in cancer. The company’s emerging pipeline of immune normalizers includes initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer.
The Series B financing follows Normunity’s successful Series A funding, which raised $65 million in 2022. The company’s progress in discovering and advancing its lead program has been impressive, with NRM-823 showing potential to address a previously unrecognized target that plays a role in supporting cancer survival across a range of solid tumors. The new funding will enable Normunity to continue its strong momentum, advancing its pipeline of novel anti-cancer therapies and exploring other modalities against this tumor-specific target, including antibody-drug conjugates and radiotheranostics.
Normunity’s unique model of collaboration with academic institutions and its focus on novel targets and mechanisms of action position it as a leader in the field of precision immuno-oncology. The company’s commitment to developing life-changing medicines for cancer patients is underscored by its ongoing efforts to advance its pipeline and explore new avenues of treatment. With this latest round of funding, Normunity is poised to make significant strides in the fight against cancer, leveraging its innovative approach and expertise to bring new hope to patients and families affected by this devastating disease.
See more funded startups in USA.